Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-10-30

AUTHORS

Kaisa Lehtiö, Vesa Oikonen, Samuel Nyman, Tove Grönroos, Anne Roivainen, Olli Eskola, Heikki Minn

ABSTRACT

. Fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) is a nitroimidazole compound that is potentially useful as a hypoxia marker in positron emission tomography (PET) studies of oncological patients. Our aim was to develop a simple protocol to quantitate uptake of [18F]FETNIM in hypoxic tumours. Dynamic imaging data from ten patients with head and neck cancer undergoing [18F]FETNIM PET was used in simulations and model fits to assess hypoxia marker uptake under different levels of blood flow. The distribution volume determined from dynamic PET study was compared with simple tumour to plasma and tumour to muscle ratios at 90–120 min. In skeletal muscle having a low but variable blood flow [2–6 ml/(100 g×min)], differences in hypoxia-specific uptake of [18F]FETNIM remain small and may be hard to detect with PET. At higher blood flow [>20 ml/(100 g×min)], the retention of [18F]FETNIM reflects the oxygenation status well and results in satisfactory contrast between hypoxic and well-oxygenated tissue. A good estimate of tissue hypoxia is accomplished by measuring the tissue to plasma [18F]FETNIM activity ratio using only a few late time points. The increased hypoxia-specific retention of [18F]FETNIM in tissues with high blood flow, such as malignant tumours, may facilitate application of [18F]FETNIM as a hypoxia marker in oncological patients. In the assessment of the tumour to non-target uptake ratio, plasma is the preferred reference tissue rather than muscle, which may show a more heterogeneous tracer uptake not easily controlled for. More... »

PAGES

101-108

References to SciGraph publications

  • 1995-03. Nitroimidazoles and imaging hypoxia in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00259-002-1016-x

    DOI

    http://dx.doi.org/10.1007/s00259-002-1016-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1015209333

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/12483416


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Flow Velocity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Squamous Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Hypoxia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fluorine Radioisotopes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Head and Neck Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Muscle, Skeletal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nitroimidazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oxygen Radioisotopes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Radiopharmaceuticals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Reproducibility of Results", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sensitivity and Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, Emission-Computed", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lehti\u00f6", 
            "givenName": "Kaisa", 
            "id": "sg:person.01047176562.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047176562.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, University of Turku, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, University of Turku, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Oikonen", 
            "givenName": "Vesa", 
            "id": "sg:person.0633127700.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633127700.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, University of Turku, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, University of Turku, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nyman", 
            "givenName": "Samuel", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, Medicity Research Laboratory, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, Medicity Research Laboratory, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gr\u00f6nroos", 
            "givenName": "Tove", 
            "id": "sg:person.01102756462.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102756462.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Roivainen", 
            "givenName": "Anne", 
            "id": "sg:person.01031503426.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031503426.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, Radiopharmaceutical Chemistry Laboratory, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, Radiopharmaceutical Chemistry Laboratory, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eskola", 
            "givenName": "Olli", 
            "id": "sg:person.01310420600.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310420600.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.470895.7", 
              "name": [
                "Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Minn", 
            "givenName": "Heikki", 
            "id": "sg:person.0700413711.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700413711.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01081524", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020842283", 
              "https://doi.org/10.1007/bf01081524"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2002-10-30", 
        "datePublishedReg": "2002-10-30", 
        "description": "Abstract. Fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) is a nitroimidazole compound that is potentially useful as a hypoxia marker in positron emission tomography (PET) studies of oncological patients. Our aim was to develop a simple protocol to quantitate uptake of [18F]FETNIM in hypoxic tumours. Dynamic imaging data from ten patients with head and neck cancer undergoing [18F]FETNIM PET was used in simulations and model fits to assess hypoxia marker uptake under different levels of blood flow. The distribution volume determined from dynamic PET study was compared with simple tumour to plasma and tumour to muscle ratios at 90\u2013120\u00a0min. In skeletal muscle having a low but variable blood flow [2\u20136\u00a0ml/(100\u00a0g\u00d7min)], differences in hypoxia-specific uptake of [18F]FETNIM remain small and may be hard to detect with PET. At higher blood flow [>20\u00a0ml/(100\u00a0g\u00d7min)], the retention of [18F]FETNIM reflects the oxygenation status well and results in satisfactory contrast between hypoxic and well-oxygenated tissue. A good estimate of tissue hypoxia is accomplished by measuring the tissue to plasma [18F]FETNIM activity ratio using only a few late time points. The increased hypoxia-specific retention of [18F]FETNIM in tissues with high blood flow, such as malignant tumours, may facilitate application of [18F]FETNIM as a hypoxia marker in oncological patients. In the assessment of the tumour to non-target uptake ratio, plasma is the preferred reference tissue rather than muscle, which may show a more heterogeneous tracer uptake not easily controlled for.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00259-002-1016-x", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1297401", 
            "issn": [
              "1619-7070", 
              "1619-7089"
            ], 
            "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "30"
          }
        ], 
        "keywords": [
          "high blood flow", 
          "blood flow", 
          "oncological patients", 
          "hypoxia markers", 
          "positron emission tomography study", 
          "emission tomography studies", 
          "later time points", 
          "neck cancer", 
          "tissue hypoxia", 
          "malignant tumors", 
          "oxygenation status", 
          "simple tumors", 
          "muscle ratio", 
          "distribution volume", 
          "tumor hypoxia", 
          "PET studies", 
          "tumors", 
          "patients", 
          "tomography study", 
          "marker uptake", 
          "skeletal muscle", 
          "time points", 
          "uptake ratio", 
          "reference tissue", 
          "quantifying tumor hypoxia", 
          "dynamic PET studies", 
          "fluoroerythronitroimidazole", 
          "tissue", 
          "nitroimidazole compounds", 
          "hypoxia", 
          "hypoxic", 
          "muscle", 
          "variable blood flow", 
          "dynamic imaging data", 
          "markers", 
          "PET", 
          "imaging data", 
          "uptake", 
          "cancer", 
          "study", 
          "activity ratio", 
          "status", 
          "aim", 
          "min", 
          "head", 
          "model fit", 
          "satisfactory contrast", 
          "ratio", 
          "assessment", 
          "retention", 
          "levels", 
          "differences", 
          "plasma", 
          "protocol", 
          "different levels", 
          "contrast", 
          "volume", 
          "tracer", 
          "data", 
          "simple protocol", 
          "heterogeneous tracer", 
          "flow", 
          "results", 
          "compounds", 
          "point", 
          "best estimate", 
          "estimates", 
          "fit", 
          "applications", 
          "simulations"
        ], 
        "name": "Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio", 
        "pagination": "101-108", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1015209333"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00259-002-1016-x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "12483416"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00259-002-1016-x", 
          "https://app.dimensions.ai/details/publication/pub.1015209333"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_362.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00259-002-1016-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1016-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1016-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1016-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1016-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    234 TRIPLES      21 PREDICATES      109 URIs      100 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00259-002-1016-x schema:about N023a4880b017456b9e2c81df630a6336
    2 N11a09e00db4f49119e6813194dc67a08
    3 N664138840bda40dca4eb0209d6df57c7
    4 N73123bbe579e482a99c8c5a20e169a87
    5 N743970c2b33a45d783dd5f3737f26134
    6 N7e43cb4374af42c0815c41fe9888c65c
    7 N82f7dd211c4b4425b826f65f7cd99f60
    8 N8f141498ca674d378a9776e3a4a119cf
    9 Na9b4774b4f4e48e8a1f2d51411cd58c0
    10 Nc68c705a43674092a0e1fc6642e037ee
    11 Nc8bc86c148fd4842b4de4b7c39f2a053
    12 Ne4229e3435c54a81ac7fcad067e84ac2
    13 Nec27ed695481488fb2b78cea9c82465d
    14 anzsrc-for:11
    15 anzsrc-for:1112
    16 schema:author Nd9b4ace891364b9c9471fe5add2e090a
    17 schema:citation sg:pub.10.1007/bf01081524
    18 schema:datePublished 2002-10-30
    19 schema:datePublishedReg 2002-10-30
    20 schema:description Abstract. Fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) is a nitroimidazole compound that is potentially useful as a hypoxia marker in positron emission tomography (PET) studies of oncological patients. Our aim was to develop a simple protocol to quantitate uptake of [18F]FETNIM in hypoxic tumours. Dynamic imaging data from ten patients with head and neck cancer undergoing [18F]FETNIM PET was used in simulations and model fits to assess hypoxia marker uptake under different levels of blood flow. The distribution volume determined from dynamic PET study was compared with simple tumour to plasma and tumour to muscle ratios at 90–120 min. In skeletal muscle having a low but variable blood flow [2–6 ml/(100 g×min)], differences in hypoxia-specific uptake of [18F]FETNIM remain small and may be hard to detect with PET. At higher blood flow [>20 ml/(100 g×min)], the retention of [18F]FETNIM reflects the oxygenation status well and results in satisfactory contrast between hypoxic and well-oxygenated tissue. A good estimate of tissue hypoxia is accomplished by measuring the tissue to plasma [18F]FETNIM activity ratio using only a few late time points. The increased hypoxia-specific retention of [18F]FETNIM in tissues with high blood flow, such as malignant tumours, may facilitate application of [18F]FETNIM as a hypoxia marker in oncological patients. In the assessment of the tumour to non-target uptake ratio, plasma is the preferred reference tissue rather than muscle, which may show a more heterogeneous tracer uptake not easily controlled for.
    21 schema:genre article
    22 schema:isAccessibleForFree false
    23 schema:isPartOf N5266224c64ac40eba6ef1a3adefc2892
    24 Nc4f3b356fe794907938164607b43abb0
    25 sg:journal.1297401
    26 schema:keywords PET
    27 PET studies
    28 activity ratio
    29 aim
    30 applications
    31 assessment
    32 best estimate
    33 blood flow
    34 cancer
    35 compounds
    36 contrast
    37 data
    38 differences
    39 different levels
    40 distribution volume
    41 dynamic PET studies
    42 dynamic imaging data
    43 emission tomography studies
    44 estimates
    45 fit
    46 flow
    47 fluoroerythronitroimidazole
    48 head
    49 heterogeneous tracer
    50 high blood flow
    51 hypoxia
    52 hypoxia markers
    53 hypoxic
    54 imaging data
    55 later time points
    56 levels
    57 malignant tumors
    58 marker uptake
    59 markers
    60 min
    61 model fit
    62 muscle
    63 muscle ratio
    64 neck cancer
    65 nitroimidazole compounds
    66 oncological patients
    67 oxygenation status
    68 patients
    69 plasma
    70 point
    71 positron emission tomography study
    72 protocol
    73 quantifying tumor hypoxia
    74 ratio
    75 reference tissue
    76 results
    77 retention
    78 satisfactory contrast
    79 simple protocol
    80 simple tumors
    81 simulations
    82 skeletal muscle
    83 status
    84 study
    85 time points
    86 tissue
    87 tissue hypoxia
    88 tomography study
    89 tracer
    90 tumor hypoxia
    91 tumors
    92 uptake
    93 uptake ratio
    94 variable blood flow
    95 volume
    96 schema:name Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio
    97 schema:pagination 101-108
    98 schema:productId N3db45d8957064dc393f68136214e6e3f
    99 N86883dce44fe41cc8758145fc568ec56
    100 N9b9ed407ee2e4656b32ea457ff535398
    101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015209333
    102 https://doi.org/10.1007/s00259-002-1016-x
    103 schema:sdDatePublished 2022-09-02T15:49
    104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    105 schema:sdPublisher N8badac9c37ce465598854299b0b294e3
    106 schema:url https://doi.org/10.1007/s00259-002-1016-x
    107 sgo:license sg:explorer/license/
    108 sgo:sdDataset articles
    109 rdf:type schema:ScholarlyArticle
    110 N023a4880b017456b9e2c81df630a6336 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Carcinoma, Squamous Cell
    112 rdf:type schema:DefinedTerm
    113 N11a09e00db4f49119e6813194dc67a08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Oxygen Radioisotopes
    115 rdf:type schema:DefinedTerm
    116 N3db45d8957064dc393f68136214e6e3f schema:name pubmed_id
    117 schema:value 12483416
    118 rdf:type schema:PropertyValue
    119 N45db81c64a3142ca92ddc645a05e4187 rdf:first sg:person.01310420600.55
    120 rdf:rest Ne3d80280a85c45648b9e8640e7629655
    121 N4f876ea84fdc4f5895ecbea43324b114 rdf:first sg:person.01102756462.43
    122 rdf:rest N5a40fe38a0ed4093be1d686e65508def
    123 N5266224c64ac40eba6ef1a3adefc2892 schema:issueNumber 1
    124 rdf:type schema:PublicationIssue
    125 N5569579443e94a68a5f3591618412261 schema:affiliation grid-institutes:grid.470895.7
    126 schema:familyName Nyman
    127 schema:givenName Samuel
    128 rdf:type schema:Person
    129 N5a40fe38a0ed4093be1d686e65508def rdf:first sg:person.01031503426.04
    130 rdf:rest N45db81c64a3142ca92ddc645a05e4187
    131 N610e824b9cdb4ca6b4517cd941b12c43 rdf:first N5569579443e94a68a5f3591618412261
    132 rdf:rest N4f876ea84fdc4f5895ecbea43324b114
    133 N653cbc7aecc7406f8eee859c748e3082 rdf:first sg:person.0633127700.74
    134 rdf:rest N610e824b9cdb4ca6b4517cd941b12c43
    135 N664138840bda40dca4eb0209d6df57c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Radiopharmaceuticals
    137 rdf:type schema:DefinedTerm
    138 N73123bbe579e482a99c8c5a20e169a87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Blood Flow Velocity
    140 rdf:type schema:DefinedTerm
    141 N743970c2b33a45d783dd5f3737f26134 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Tomography, Emission-Computed
    143 rdf:type schema:DefinedTerm
    144 N7e43cb4374af42c0815c41fe9888c65c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Fluorine Radioisotopes
    146 rdf:type schema:DefinedTerm
    147 N82f7dd211c4b4425b826f65f7cd99f60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Nitroimidazoles
    149 rdf:type schema:DefinedTerm
    150 N86883dce44fe41cc8758145fc568ec56 schema:name doi
    151 schema:value 10.1007/s00259-002-1016-x
    152 rdf:type schema:PropertyValue
    153 N8badac9c37ce465598854299b0b294e3 schema:name Springer Nature - SN SciGraph project
    154 rdf:type schema:Organization
    155 N8f141498ca674d378a9776e3a4a119cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Humans
    157 rdf:type schema:DefinedTerm
    158 N9b9ed407ee2e4656b32ea457ff535398 schema:name dimensions_id
    159 schema:value pub.1015209333
    160 rdf:type schema:PropertyValue
    161 Na9b4774b4f4e48e8a1f2d51411cd58c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Sensitivity and Specificity
    163 rdf:type schema:DefinedTerm
    164 Nc4f3b356fe794907938164607b43abb0 schema:volumeNumber 30
    165 rdf:type schema:PublicationVolume
    166 Nc68c705a43674092a0e1fc6642e037ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Cell Hypoxia
    168 rdf:type schema:DefinedTerm
    169 Nc8bc86c148fd4842b4de4b7c39f2a053 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Muscle, Skeletal
    171 rdf:type schema:DefinedTerm
    172 Nd9b4ace891364b9c9471fe5add2e090a rdf:first sg:person.01047176562.24
    173 rdf:rest N653cbc7aecc7406f8eee859c748e3082
    174 Ne3d80280a85c45648b9e8640e7629655 rdf:first sg:person.0700413711.55
    175 rdf:rest rdf:nil
    176 Ne4229e3435c54a81ac7fcad067e84ac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Reproducibility of Results
    178 rdf:type schema:DefinedTerm
    179 Nec27ed695481488fb2b78cea9c82465d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Head and Neck Neoplasms
    181 rdf:type schema:DefinedTerm
    182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    183 schema:name Medical and Health Sciences
    184 rdf:type schema:DefinedTerm
    185 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    186 schema:name Oncology and Carcinogenesis
    187 rdf:type schema:DefinedTerm
    188 sg:journal.1297401 schema:issn 1619-7070
    189 1619-7089
    190 schema:name European Journal of Nuclear Medicine and Molecular Imaging
    191 schema:publisher Springer Nature
    192 rdf:type schema:Periodical
    193 sg:person.01031503426.04 schema:affiliation grid-institutes:grid.470895.7
    194 schema:familyName Roivainen
    195 schema:givenName Anne
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031503426.04
    197 rdf:type schema:Person
    198 sg:person.01047176562.24 schema:affiliation grid-institutes:grid.470895.7
    199 schema:familyName Lehtiö
    200 schema:givenName Kaisa
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047176562.24
    202 rdf:type schema:Person
    203 sg:person.01102756462.43 schema:affiliation grid-institutes:grid.470895.7
    204 schema:familyName Grönroos
    205 schema:givenName Tove
    206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102756462.43
    207 rdf:type schema:Person
    208 sg:person.01310420600.55 schema:affiliation grid-institutes:grid.470895.7
    209 schema:familyName Eskola
    210 schema:givenName Olli
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310420600.55
    212 rdf:type schema:Person
    213 sg:person.0633127700.74 schema:affiliation grid-institutes:grid.470895.7
    214 schema:familyName Oikonen
    215 schema:givenName Vesa
    216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633127700.74
    217 rdf:type schema:Person
    218 sg:person.0700413711.55 schema:affiliation grid-institutes:grid.470895.7
    219 schema:familyName Minn
    220 schema:givenName Heikki
    221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700413711.55
    222 rdf:type schema:Person
    223 sg:pub.10.1007/bf01081524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020842283
    224 https://doi.org/10.1007/bf01081524
    225 rdf:type schema:CreativeWork
    226 grid-institutes:grid.470895.7 schema:alternateName Turku PET Centre, Medicity Research Laboratory, Turku, Finland
    227 Turku PET Centre, Radiopharmaceutical Chemistry Laboratory, Turku, Finland
    228 Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland
    229 Turku PET Centre, University of Turku, Turku, Finland
    230 schema:name Turku PET Centre, Medicity Research Laboratory, Turku, Finland
    231 Turku PET Centre, Radiopharmaceutical Chemistry Laboratory, Turku, Finland
    232 Turku PET Centre, Turku University Central Hospital, PO Box 52, 20521 Turku, Finland
    233 Turku PET Centre, University of Turku, Turku, Finland
    234 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...